FDA in Jan 2022. Phase I/II studies will begin enrollment in the first half of 2022 for the treatment of advanced solid tumors and lymphomas. Ambagon Therapeutics, another molecular glue drug discovery company, applies a new approach to a challenging target class -the intrinsically disordered proteins. It involves forcing disordered proteins to acquire a druggable interface using molecular glues to stabilize their interaction with 14-3-3 adaptor proteins, a signaling hub for critical cell processes. It recently announced an ambitious program to augment its drug discovery platform and to advance its pipeline of molecular glues.